Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04577664
Other study ID # Thyroid surgery
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 2020
Est. completion date December 2021

Study information

Verified date October 2020
Source Assiut University
Contact ahmed nasr ahmed, resident doctor
Phone +201064594779
Email zorakovic11@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of work is to compare between subtotal and total thyroidectomy intra and postoperatively to identify which technique is better for patient of graves disease


Description:

Graves' disease is an autoimmune disease that affects the thyroid gland[1] and it's the most common cause of hyperthyroidism. [2] Treatment of Graves' disease includes antithyroid drugs ; radioiodine ; and thyroidectomy . patients with Graves' hyperthyroidism can be treated with any of these treatment options. There is a wide geographic variation in the choice of therapy.[3] Medical treatment with antithyroid drugs is often accepted as first-choice modality in Europe, followed by radioiodine in case of recurrence. Although surgery offers the advantage of quick control and low morbidity in experienced hands, it is infrequently recommended as initial treatment. Therapy with radioiodine is the most common treatment in the United States, while antithyroid drugs and/or thyroidectomy are used more often in Europe, Japan, and most of the rest of the world.recent literature shows that the relapse rate was the highest among patients who received antithyroid drugs (40%) as compared to those who received radioiodine (21%) or Surgery (5). [4] Two different surgical techniques are used for the treatment of Graves' hyperthyroidism: a total thyroidectomy (TT) in which the entire gland is removed and a subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams. Although thyroidectomy has been broadly considered as a viable alternative theapy for patients with Graves' disease , the resection extent and remnant size of thyroid gland remains controversial.[6] Although total thyroidectomy has a lower recurrence rate it has raised a concern that a more radical operation would increase the complications.[7] we intend to perform this analysis based on the published literatures of randomized controlled trials to evaluate the specific risks of thyroid surgery including recurrent hyperthyroididm , post-operative bleeding , recurrent laryngeal nerve injury , hypoparathyroidism and opthalmopathy progression.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 2021
Est. primary completion date November 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- patients diagnosed clinically, biochemically and immunologically with Graves' disease who will undergo thyroidectomy at general surgery department in AUH.

Exclusion Criteria:

- 1- previous thyroid or parathyroid surgery.

- 2- recurrent hyperthyroidism after radioiodine therapy.

- 3- preoperative recurrent laryngeal nerve palsy.

- 4- patients unfit for operation.

- 5- inability to comply with the follow-up protocol.

- 6- suspicious thyroid nodules.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
total thyroidectomy
a total thyroidectomy (TT) in which the entire gland is removed
subtotal thyroidectomy
subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (2)

Maurer E, Maschuw K, Reuss A, Zieren HU, Zielke A, Goretzki P, Simon D, Dotzenrath C, Steinmüller T, Jähne J, Kemen M, Coerper S, Leister I, Nies C, Hartel M, Türler A, Holzer K, Agha A, Knoop M, Musholt T, Aminossadati B, Bartsch DK. Total Versus Near-total Thyroidectomy in Graves Disease: Results of the Randomized Controlled Multicenter TONIG-trial. Ann Surg. 2019 Nov;270(5):755-761. doi: 10.1097/SLA.0000000000003528. — View Citation

Sugino K, Nagahama M, Kitagawa W, Ohkuwa K, Uruno T, Matsuzu K, Suzuki A, Tomoda C, Y Hames K, Akaishi J, Masaki C, Ogimi Y, Yabuta T, Ito K. Change of surgical strategy for Graves' disease from subtotal thyroidectomy to total thyroidectomy: a single institutional experience. Endocr J. 2019 Feb 28;66(2):181-186. doi: 10.1507/endocrj.EJ18-0324. Epub 2018 Dec 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary comparison between total thyroidectomy vs subtotal thyroidectomy in graves' disease Prevlance of recurrent hyperthyroidism baseline
Secondary comparison between total thyroidectomy vs subtotal thyroidectomy in graves' disease Postoperative hypocalcemia and hypoparathyroidism. baseline
See also
  Status Clinical Trial Phase
Completed NCT04782856 - Energy Metabolism in Thyroidectomized Patients Phase 2
Completed NCT02194920 - Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function N/A
Recruiting NCT05510609 - Three-dimensional Ultrasonography Thyroid Volume Measurement. N/A
Unknown status NCT02140476 - Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy N/A
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Recruiting NCT04410601 - Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT N/A
Completed NCT05180214 - Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it. Phase 2
Completed NCT03969108 - Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Phase 4